People living with spinal muscular atrophy (SMA) in England are set to gain routine access to two potentially life-changing treatments, following our publication of final draft guidance today.
We’ve recommended that newborn babies receiving antibiotics in hospital could potentially switch to oral antibiotics and be cared for at home if they are doing well and responding to treatment.
Around 530 people in England will benefit from access to the Duchenne muscular dystrophy treatment givinostat, following the successful negotiation of a commercial deal to make the medicine available on the NHS.
The change follows a landmark guideline published jointly in 2024 by NICE, the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN).
In Dudley, an asthma clinic is catching people before they reach crisis point, diagnosing faster and making sure patients have the right treatment from the start - referral times have fallen from over a year to under 6 weeks.
NICE-recommended healthtech found the cause of Peter’s stroke. Read his story and discover how our guidance is helping life-changing innovations reach the patients who need them.
NICE has been commissioned by the Department of Health and Social Care and NHS England to adapt the evidence standards framework for digital health technologies to support evidence-based decision making for digital care technologies used in adult social care.
Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on licensing and value.
